PALATINE, Ill., June 2, 2008 (PRIME NEWSWIRE) -- Acura Pharmaceuticals, Inc. (Nasdaq:ACUR) today announced that clinical evaluation is now allowed under an active Investigational New Drug application (“IND”) for a second undisclosed opioid analgesic product candidate using Aversion(r) Technology. This product candidate was previously licensed by Acura to King Pharmaceuticals Research and Development, Inc., a wholly owned subsidiary of King Pharmaceuticals, Inc. (“King”) as a result of the License, Development and Commercialization Agreement between the companies. Acura and King are jointly developing opioid analgesic product candidates utilizing Acura’s proprietary Aversion(r) Technology. These product candidates are intended to deter common methods of prescription drug misuse and abuse.
